Circulating tumor DNA profiling by next generation sequencing reveals heterogeneity of crizotinib resistance mechanisms in a gastric cancer patient with MET amplification-Reference-Cited by-同舟云学术

Circulating tumor DNA profiling by next generation sequencing reveals heterogeneity of crizotinib resistance mechanisms in a gastric cancer patient with MET amplification

Published:2017-02-17 Issue:16 Volume:8 Page:26281-26287
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Du Juan¹,Wu Xue²,Tong Xiaoling²,Wang Xiaonan³,Wei Jia¹,Yang Yang¹,Chang Zhili³,Mao Yu³,Shao Yang W²,Liu Baorui¹

Affiliation:

1. The Comprehensive Cancer Centre of Drum Tower Hospital, Medical School of Nanjing University, Clinical Cancer Institute of Nanjing University, Nanjing, Jiangsu, 210008, China

2. Geneseeq Technology Inc., Toronto, Ontario, M5G1L7, Canada

3. Nanjing Geneseeq Technology Inc., Sino-Danish Life Science Park, Nanjing, Jiangsu, 210032, China

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical applications and perspectives of circulating tumor DNA in gastric cancer;Cancer Cell International;2024-01-06

2. Targeting MET amplification in Gastro-oesophageal (GO) malignancies and overcoming MET inhibitor resistance: challenges and opportunities;Expert Review of Gastroenterology & Hepatology;2022-06-30

3. ctDNA analysis in the personalized clinical management of gastroesophageal adenocarcinoma: turning hope into reality;Future Oncology;2021-11

4. Clinical Applications of Liquid Biopsy in Gastric Cancer;Frontiers in Medicine;2021-09-28

5. Quantitative characterization of tumor cell-free DNA shortening;BMC Genomics;2020-07-10